CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.12% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Roche Holding AG (Participation) - ROGz CFD

294.8
0.27%
Market Trading Hours* (UTC) Opens on Monday at 08:00

Mon - Fri: 08:00 - 16:20

  • Summary
  • Historical Data
Trading сonditions
Spread 4.4
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.012201 %
Charges from full value of position ($-2.32)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.012201%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.010022 %
Charges from full value of position ($-1.90)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.010022%
Overnight fee time 22:00 (UTC)
Min traded quantity 0.1
Currency CHF
Margin 5.00%
Stock exchange Switzerland
Commission on trade 0%

Key Stats
Prev. Close 294
Open 294.1
1-Year Change 26.93%
Day's Range 293 - 297.6
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 21, 2025 294.8 1.6 0.55% 293.2 297.8 292.4
Feb 20, 2025 294.0 1.3 0.44% 292.7 294.1 289.1
Feb 19, 2025 289.7 -0.4 -0.14% 290.1 296.4 289.7
Feb 18, 2025 294.5 1.6 0.55% 292.9 294.8 291.9
Feb 17, 2025 294.3 -1.3 -0.44% 295.6 295.6 289.0
Feb 14, 2025 290.7 -6.6 -2.22% 297.3 297.5 287.9
Feb 13, 2025 297.4 4.0 1.36% 293.4 297.7 291.6
Feb 12, 2025 290.7 2.0 0.69% 288.7 291.3 286.5
Feb 11, 2025 287.9 -1.0 -0.35% 288.9 290.1 287.9
Feb 10, 2025 289.6 2.3 0.80% 287.3 289.7 285.8
Feb 7, 2025 288.4 2.9 1.02% 285.5 290.5 285.0
Feb 6, 2025 285.3 -5.9 -2.03% 291.2 291.7 285.3
Feb 5, 2025 290.4 3.9 1.36% 286.5 290.9 282.4
Feb 4, 2025 280.2 -4.5 -1.58% 284.7 286.0 280.2
Feb 3, 2025 285.3 1.4 0.49% 283.9 286.4 280.2
Jan 31, 2025 285.7 -2.8 -0.97% 288.5 288.8 283.2
Jan 30, 2025 285.8 9.1 3.29% 276.7 286.8 275.5
Jan 29, 2025 281.0 1.2 0.43% 279.8 282.4 279.2
Jan 28, 2025 275.1 -3.3 -1.19% 278.4 283.1 275.1
Jan 27, 2025 279.4 4.1 1.49% 275.3 280.0 274.6

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Roche Company profile

About Roche Holding AG

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Roche Holding AG revenues increased 8% to SF62.8B. Net income decreased 3% to SF13.93B. Revenues reflect Diagnostics segment increase of 29% to SF17.76B, Chugai segment increase of 20% to SF4.51B, Rest of Europe segment increase of 16% to SF11.38B, Rest of Asia segment increase of 13% to SF9.75B, Germany segment increase of 29% to SF4.29B.

Equity composition

3 April 2001, 100 for 1 stock split.

Industry: Pharmaceuticals (NEC)

Grenzacherstrasse 124
BASEL
BASEL-STADT 4058
CH

People also watch

BTC/USD

96,660.70 Price
+1.410% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

Gold

2,936.56 Price
-0.110% 1D Chg, %
Long position overnight fee -0.0149%
Short position overnight fee 0.0067%
Overnight fee time 22:00 (UTC)
Spread 0.30

US100

21,594.40 Price
-2.120% 1D Chg, %
Long position overnight fee -0.0235%
Short position overnight fee 0.0013%
Overnight fee time 22:00 (UTC)
Spread 7.0

ETH/USD

2,769.34 Price
+4.920% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

Still looking for a broker you can trust?

Join the 690,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading